canfour: targeting il1rap for nsclc or pancreatic cancer
Published 5 years ago • 358 plays • Length 3:34Download video MP4
Download video MP3
Similar videos
-
3:20
the emerging roles of ngs and liquid biopsies in pancreatic cancer
-
7:25
cantargia - executive interview
-
16:14
cantargia ab @ sachs_elsf
-
4:47
checkmate 227: combining ctla-4 and pd-l1 in nsclc
-
0:44
com503: the next steps in harnessing cytokines to treat cancer
-
29:47
early identification of target candidates for pancreatic adenocarcinoma immunotherapy
-
1:25
p2x7 activation can trigger il-1β release by human macrophages in an nlrp3-independent manner
-
2:19
combining ctla-4 agents with pd-1/pd-l1 agents in lung cancer
-
1:09
inconspicuous protein key to deadly blood cancer
-
3:48
ciltacabtagene autoleucel improves outcomes in patients with len-refractory fhr mm
-
1:59
researchers testing new method that could potentially help treat pancreatic cancer
-
2:08
using first-line immunotherapy in stage 4 nsclc
-
1:04
advances in the management of pancreatic cancer - line 4 stop 1 advanced pdac targets
-
4:17
ciltacabtagene autoleucel greatly reduces risk of disease progression in lenalidomide-refractory mm
-
1:01
supplements are tolerable for patients with pancreatic cancer
-
4:22
syndecan-4 is a signaling protein that facilitates pancreatic cancer progression
-
2:54
pioneer: understanding pd-l1 resistances in non-small cell lung cancer
-
17:38
deciding the initial chemotherapy for patients with metastatic pancreatic cancer
-
1:32
the calcium channel trpm2: a cancer contributor and therapeutic target